Hello, Fool! | Login | Signup | My Fool
Jul 23, 2008 5:56 PM ET | Site Changes | Help
Search: Tickers Company Names Players
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
View Ticker Page (BMRN)
Results 1 - 10 of 102 : 12345Next »
Recs
TMFBreakerJava (99.27) Submitted: 9/26/07 10:22 AM : Start Price: $24.50 BMRN Score: 42.16
With Kuvan in line to be reviewed soon by the FDA, and very positive phase III results, the likelihood is high that approval will be secured for this treatment for Phenylketonuria. This will give Biomarin a third highly profitable drug on the market...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
JSIMMS001 (96.28) Submitted: 8/24/06 10:43 AM : Start Price: $15.70 BMRN Score: 98.76
This Company has already outperformed the S&P this year and is on Pace to do it again next year. With new drugs coming out of the pipeline and an increasing client base. This Company should prove a solid hold for the next few years.
TMFBreakerCharly (30.12) Submitted: 4/27/06 1:35 AM : Start Price: $12.13 BMRN Score: 156.61
This company has very good products for rare genetic diseases and absolutely no competition. The company is probably worth $25 if its drug Phenoptin works. I expect it will get bought out at some point in the next few years as its pipeline is pretty ...
NetscribeBiotech (78.76) Submitted: 5/23/07 8:34 AM : Start Price: $18.67 BMRN Score: 82.11
BioMarin Pharmaceutical Inc’s core business strategy is to develop drugs for which there are no medications in the market. The up-side to this strategy would be ready availability of market for its product without competitive threats. The down side w...
Westerlees (< 20) Submitted: 1/30/07 2:00 AM : Start Price: $19.00 BMRN Score: 72.99
BioMarin's focus is on Orphan Drugs. These are drugs for diseases for which no one else has a cure, or really is working to find one because the patient population is small, and therefore not an attractive market for big Pharma companies looking for ...
snazzysnazz (< 20) Submitted: 1/18/07 12:34 PM : Start Price: $17.45 BMRN Score: 85.94
Great pipeline and future outlook on their own. Also a great buy-out opportunity for one of the big boys. All in all, this stock will double in the next year or so with or without a buy-out. Hang on to this one!!!
gaals (48.06) Submitted: 8/25/06 6:04 AM : Start Price: $15.66 BMRN Score: 98.88
I mainly put this one on here because I think it is getting an unfairly bad rap on the CAPS rating.
bmw201030 (96.69) Submitted: 10/06/06 6:33 PM : Start Price: $15.97 BMRN Score: 98.91
The Orphan Drug status gives BMRN a virtual monopoly for close to the next decade. It's a wide moat for now, I expect this to outperform the market the next 2-7 years.
KatWoman50 (95.56) Submitted: 3/10/08 3:49 PM : Start Price: $37.48 BMRN Score: -12.10
Small biotech company with several enzyme replacment drugs in clinical trials. Kuvan was apploved in January for treatment of a rare genetic disease. Company should become profitable last half of 2008
Phileas100 (76.49) Submitted: 4/18/07 9:29 AM : Start Price: $16.50 BMRN Score: 100.30
This company is doing good research in drugs that address orphan desaeses (those that no other labs are paying attention to). This provides a wide moat.They issued convertible notes that may dilute EPS in the future, but I a...
Terms & Conditions
RSS Headlines
Fool UK